Malaysia's BiotechCorp Sees More Than Double Revenue Target Achieved
This article was originally published in PharmAsia News
The state-run Malaysian Biotechnology Corp said the companies it supports under BioNexus are expected to reach combined foreign investments of nearly $1 billion by the end of the year, in contrast to last year's $340 million.
You may also be interested in...
A European pilot project that lets drug companies developing innovative products receive scientific advice from two EU member states at the same time is proving its worth during the pandemic.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.